BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 08:34:33 22/05/2024 BST			5-day change	1st Jan Change
10.1 ^GBX	-8.18%		-12.17%	-3.81%

04-17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
04-17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

BiVictriX Therapeutics reports "really exciting" BCX001 data

February 01, 2023 at 12:35 pm

(via NewsDirect)

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Proactive's Thomas Warner after reporting positive results from a preclinical study of lead molecule BVX001, that she describes as "really exciting." Thorn explains the significance of the results and reveals how the business intends to move forward with the molecule having now established its "highly favourable" safety profile.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about BiVictriX Therapeutics Plc

Bivictrix granted FDA orphan drug status for rare cancer treatment	04-17	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	04-17	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	12-05	CI
Bivictrix selects final sequences for lead tumour programme	11-30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	11-30	CI
BiVictriX patent boost; 4Global deal extended	11-15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	11-15	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	11-15	RE
Bivictrix says BVX001 increases survival rates by more than double	12/10/23	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	12/10/23	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	12/10/23	RE
Bivictrix hires new CFO as Alex Hughes steps down after seven months	03/10/23	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	03/10/23	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	03/10/23	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	03/10/23	CI
AEW UK REIT appoints new chair; Oberon raises money	19/09/23	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	19/09/23	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	19/09/23	CI
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress	23/08/23	AN
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23/08/23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23/08/23	MT
Bivictrix Therapeutics raises GBP2.1 million through fundraise	19/07/23	AN
Bivictrix to raise more than GBP2 million via placing	19/07/23	AN
Bivictrix Therapeutics hails positive data in final leukaemia study	17/07/23	AN
Bivictrix Therapeutics hails positive leukaemia test results	19/06/23	AN

Chart BiVictriX Therapeutics Plc

Duration

Period

More charts

Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

17/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.11 GBP

Average target price

0.66 GBP

Spread / Average Target

+500.00%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	-3.81%	11.54M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.96%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research